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Abstract
Introduction
• Polycystic Ovarian Syndrome (PCOS) is the leading cause of 
anovulatory infertility and the most common endocrinopathy in 
women of reproductive age (Rosenfield & Ehrmann, 2016) 
• Currently, the first-line treatment for infertility associated with 
PCOS is clomiphene citrate, which was introduced in the 1960s 
(Morad & Farag, 2015). However, it has been proposed that an 
aromatase inhibitor, specifically letrozole, should become the 
first-line treatment for these patients due to a decreased adverse 
effect profile, a lower incidence of simultaneous multiple 
gestation pregnancies, and a decreased risk of congenital 
abnormalities
Research Question
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Discussion
.
• PURPOSE: To determine if letrozole is an equal or better 
alternative to clomiphene citrate for infertility treatment in PCOS 
patients
• LITERATURE REVIEW: Letrozole was found to have higher 
ovulation rates, fewer twin pregnancies/more single births, higher 
pregnancy rates, and higher live birth rates compared to 
clomiphene citrate. There were conflicting results for endometrial 
thickness and single follicle stimulation. Neither letrozole or 
clomiphene citrate was superior to the other for ovarian 
hyperstimulation syndrome. There were no significant differences 
between letrozole and clomiphene citrate regarding congenital 
abnormalities and miscarriage rates. The results regarding ectopic 
pregnancies were comparable between both groups 
• CONCLUSION: The results provide information supporting 
letrozole as an adequate first-line alternative to clomiphene citrate 
for infertility in patients with PCOS. 
• In the patient with polycystic ovarian syndrome, is letrozole 
compared to clomiphene citrate more effective for ovulation 
induction, endometrial thickness, single follicle stimulation/single 
gestation birth, pregnancy rate, and live birth rate?
• In the patient with polycystic ovarian syndrome, is letrozole 
compared to clomiphene citrate safer for the mother and baby 
regarding ovarian hyperstimulation syndrome, congenital 
anomalies, ectopic pregnancies, and miscarriage rates?
Efficacy 
• Ghahiri et al: RCT, n=101. No significant difference regarding 
ovulation and pregnancy rates
• Sharief & Nafee: RCT, n=75. Letrozole: Lower number of mature 
follicles (p=0.0001). Letrozole: Higher endometrial thickness 
(p=0.0001). Letrozole: Higher ovulation rate (p=0.05). No 
significant difference in pregnancy rates
• Hussain et al: RCT, n=150. Letrozole: Higher ovulation rate 
(p=0.001). Letrozole: Higher single follicle ovulation (p=0.0270). 
Letrozole: Greater endometrial thickness (p=0.031). No 
significant difference regarding pregnancy rate
• Legro: RCT, n=750. Letrozole: Higher cumulative live birth rate 
(p=0.007). Letrozole: Higher ovulation rate (p<0.001). Letrozole: 
Greater single pregnancy rate (p=0.03)
• Liu et al: RCT, n=268. No significant difference regarding 
pregnancy and live birth rate. Letrozole treatment group: Higher 
ovulation rate (p<0.001)
• Amer et al: RCT, n=159. Letrozole: Higher pregnancy rate 
(p=0.022). Letrozole: Higher rate of ovulation and pregnancies 
per cycle (p=0.045, p=0.035, respectively). Clomiphene citrate: 
Greater endometrial thickness (p=0.002)
• Al-Shaikh: prospective clinical trial, n=85. Letrozole: Higher 
number of mature follicles (p<0.05). Clomiphene citrate: Higher 
endometrial thickness (p<0.05). No significant difference in 
pregnancy rates per cycle
• It is apparent that letrozole could be at the very least an equal 
alternative, with more research pointing towards an improvement in 
efficacy with letrozole compared to clomiphene citrate. 
• Infertility due to PCOS is a very common complaint and a struggle 
that is frequently brought to the provider's attention. Many women 
have tried to become pregnant with other fertility treatments to no 
avail or are beginning their infertility treatment journey. It is 
promising that with this research and ongoing research, letrozole 
will become a first-line pharmacological treatment for infertility in 
PCOS patients. Providers will be able to inform their patients of all 
treatment options available including letrozole and the positive 
impact it can have on infertility. 
• With a lower rate of multiple gestation pregnancies and a higher rate 
of ovulation, pregnancy, and live birth rates, women with infertility 
will be able to have more hope in their dreams of becoming a 
mother with the most effective medication available to them. This 
could change the provider's way of practice if the provider is able to 
offer the patient an alternative medication that is superior to the 
traditional option, and ultimately providing the best outcome 
possible for each patient. 
I would like to thank  my classmates for their continued support 
throughout this project and for helping in the editing process of this 
project. I would also like to thank my advisor, Professor Jay 
Metzger; course director, Professor Daryl Sieg; UND SMHS 
Librarian, Dawn Hackman; Statistics Professor, Ivan Blum; Sami 
and MaKayla from the UND Writing Center; and Stephanie Dahl, 
MD for their support and guidance with my project. It is greatly 
appreciated.
Statement of the Problem
• 25% of patients with infertility are clomiphene citrate resistant 
and unable to ovulate, and many are unable to conceive with 
clomiphene citrate and subsequently experience clomiphene 
citrate failure (Legro et al., 2014)
• Clomiphene citrate has also been associated with a limited 
efficacy including a 22% live birth rate and increased risk of 
multiple pregnancies (Legro et al., 2014)
• If an alternative to clomiphene citrate is available that is safer and 
more effective, it should be implemented as the first-line 
treatment in daily medical practice
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Safety
• Sharma et al: n=201. No significant difference in rate of 
congenital or chromosomal abnormalities compared to natural 
conception
• Legro et al: n=750. No significant difference in congenital 
defects, pregnancy loss, or miscarriage rate. Letrozole: Lower 
neonatal death rate and fetal death rate (p<0.05)
• Liu et al: n=63. No congenital abnormalities in either group
• Ghahiri et al: n=101. Five miscarriages in both groups. No cases 
of ovarian hyperstimulation syndrome (OHSS)
• Ovulation rate: Ghahiri et al. (2016) and Amer et al. (2017) found no 
significant difference, while Sharief & Nafee (2015), Hussain et al. 
(2013), Legro et al. (2014) and Liu et al. (2017) all found letrozole to 
have statistically significant higher ovulation rates
• Endometrial thickness: Sharief & Nafee (2015) and Hussain et al. 
(2013) found that letrozole had significantly higher endometrial 
thickness, while Al-Shaikh et al. (2017) found that clomiphene citrate 
had higher endometrial thickness
• Single follicle stimulation/single gestation birth: Sharief & Nafee 
(2015) found that letrozole had a higher rate of single follicles, while 
Al-Shaikh et al. (2017) reported letrozole to have a higher number of 
single follicles. Sharief & Nafee (2015) reported one twin pregnancy 
in the clomiphene citrate group/none in the letrozole group, and Legro 
(2014) reported a higher single pregnancy rate with letrozole
• Pregnancy rates: Legro et al. (2014) and Amer et al. (2017) found 
letrozole to have higher pregnancy rates with letrozole, other studies 
found no significant difference.
• Live birth rates: Legro et al. (2014) found letrozole to have a 
significantly higher live birth rate, while Liu (2017) found no 
significant difference
• Ovarian Hyperstimulation Syndrome (OHSS): Ghahiri et al. (2016) 
and Hussain et al. (2013) reported no cases of OHSS, while other 
studies did not disclose this information
• Congenital abnormalities: No significant difference between the two 
drugs (Sharma et al, [2014], Legro et al. [2014, Amer et al. [2017], 
and Liu et al. [2017])
• Ectopic pregnancies: rates between the studies ranged from 2%-10.3% 
in the letrozole group and 0.0%-12.5% in the clomiphene group
• Miscarriage rates: No significant findings other than Tatsumi et al. 
(2017) reporting a much lower miscarriage rate with letrozole 
compared to normal pregnancy
